APA (7th ed.) Citation

N, H., G, V., D, M., T, B., S, U., Y, C., & S, M. (2022). The impact on Anti-Mullerian Hormone (AMH), uterine fibroid size and uterine artery patency following Uterine Fibroid Embolization (UFE) with a resorbable embolic agent. Human fertility (Cambridge, England), 25(5), 881. https://doi.org/10.1080/14647273.2021.1920055

Chicago Style (17th ed.) Citation

N, Hacking, Vigneswaran G, Maclean D, Bryant T, Umranikar S, Cheong Y, and Modi S. "The Impact on Anti-Mullerian Hormone (AMH), Uterine Fibroid Size and Uterine Artery Patency Following Uterine Fibroid Embolization (UFE) with a Resorbable Embolic Agent." Human Fertility (Cambridge, England) 25, no. 5 (2022): 881. https://doi.org/10.1080/14647273.2021.1920055.

MLA (9th ed.) Citation

N, Hacking, et al. "The Impact on Anti-Mullerian Hormone (AMH), Uterine Fibroid Size and Uterine Artery Patency Following Uterine Fibroid Embolization (UFE) with a Resorbable Embolic Agent." Human Fertility (Cambridge, England), vol. 25, no. 5, 2022, p. 881, https://doi.org/10.1080/14647273.2021.1920055.